Media headlines about Auris Medical Holding AG (NASDAQ:EARS) have been trending somewhat negative this week, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Auris Medical Holding AG earned a daily sentiment score of -0.20 on Alpha One’s scale. Alpha One also gave news headlines about the biotechnology company an impact score of 75 out of 100, indicating that recent media coverage is likely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Alpha One Sentiment Analysis’s rankings:
- The Auris Medical Holding AG (EARS) Earns Daily News Impact Rating of 0.02 – BangaloreWeekly (bangaloreweekly.com)
- Needle Action Activity Spotted in Auris Medical Holding AG (EARS) – Concord Register (concordregister.com)
- Volume Moving the Tape For Auris Medical Holding AG (EARS) – JCTY News (jctynews.com)
- ValuEngine Downgrades Auris Medical Holding AG (EARS) to Strong Sell (americanbankingnews.com)
Shares of Auris Medical Holding AG (NASDAQ EARS) traded up 0.75% on Friday, reaching $0.67. The company’s stock had a trading volume of 316,129 shares. Auris Medical Holding AG has a one year low of $0.60 and a one year high of $5.45. The firm has a 50-day moving average price of $0.68 and a 200 day moving average price of $0.94. The firm’s market capitalization is $29.70 million.
Auris Medical Holding AG (NASDAQ:EARS) last announced its earnings results on Thursday, May 11th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.08. On average, analysts anticipate that Auris Medical Holding AG will post ($0.72) earnings per share for the current fiscal year.
A number of research analysts have issued reports on EARS shares. Needham & Company LLC lowered their price objective on Auris Medical Holding AG from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, March 14th. Roth Capital started coverage on Auris Medical Holding AG in a research note on Thursday, April 13th. They set a “buy” rating and a $4.50 price objective for the company. Finally, ValuEngine cut Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $5.44.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/auris-medical-holding-ag-ears-earning-somewhat-negative-press-coverage-study-finds/1899766.html
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.